UTHR UNITED THERAPEUTICS Corp
Price (delayed)
$361.1
Market cap
$16.12B
P/E Ratio
14.85
Dividend/share
N/A
EPS
$24.31
Enterprise value
$14.97B
United Therapeutics Corporation focuses on the strength of a balanced, value-creating biotechnology model. We are confident in our future thanks to our fundamental attributes, namely our obsession with quality and
Highlights
The debt has plunged by 50% YoY and by 20% from the previous quarter
The company's EPS rose by 26% YoY and by 5% QoQ
The stock's P/E is 21% above its last 4 quarters average of 12.3 and 8% above its 5-year quarterly average of 13.8
Key stats
What are the main financial stats of UTHR
Market
Valuations
Earnings
Shares outstanding
44.64M
Market cap
$16.12B
Enterprise value
$14.97B
Price to earnings (P/E)
14.85
Price to book (P/B)
2.63
Price to sales (P/S)
5.84
EV/EBIT
10.06
EV/EBITDA
9.63
EV/Sales
5.43
Revenue
$2.76B
Gross profit
$2.45B
Operating income
$1.28B
Net income
$1.11B
EBIT
$1.49B
EBITDA
$1.55B
Free cash flow
$898.1M
Per share
Balance sheet
Liquidity
EPS
$24.31
EPS diluted
$22.74
Free cash flow per share
$20.14
Book value per share
$137.13
Revenue per share
$61.8
TBVPS
$157.2
Total assets
$7.12B
Total liabilities
$1.02B
Debt
$400M
Equity
$6.1B
Working capital
$3.13B
Debt to equity
0.07
Current ratio
4.58
Quick ratio
4.2
Net debt/EBITDA
-0.74
Margins
Efficiency
Dividend
EBITDA margin
56.4%
Gross margin
88.9%
Net margin
40.3%
Operating margin
46.4%
Return on assets
16.2%
Return on equity
19.2%
Return on invested capital
29%
Return on capital employed
23.8%
Return on sales
54%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
UTHR stock price
How has the UNITED THERAPEUTICS stock price performed over time
Intraday
-1.7%
1 week
-2.56%
1 month
-1.87%
1 year
64.75%
YTD
2.34%
QTD
2.34%
Financial performance
How have UNITED THERAPEUTICS's revenue and profit performed over time
Revenue
$2.76B
Gross profit
$2.45B
Operating income
$1.28B
Net income
$1.11B
Gross margin
88.9%
Net margin
40.3%
The company's gross profit rose by 25% YoY and by 5% QoQ
The company's revenue rose by 25% YoY and by 5% QoQ
UNITED THERAPEUTICS's net income has increased by 23% YoY and by 3.9% QoQ
The operating income has grown by 16% YoY
Growth
What is UNITED THERAPEUTICS's growth rate over time
Valuation
What is UNITED THERAPEUTICS stock price valuation
P/E
14.85
P/B
2.63
P/S
5.84
EV/EBIT
10.06
EV/EBITDA
9.63
EV/Sales
5.43
The company's EPS rose by 26% YoY and by 5% QoQ
The stock's P/E is 21% above its last 4 quarters average of 12.3 and 8% above its 5-year quarterly average of 13.8
UTHR's price to book (P/B) is 25% higher than its 5-year quarterly average of 2.1 and 20% higher than its last 4 quarters average of 2.2
The equity has increased by 7% since the previous quarter and by 7% year-on-year
The company's revenue rose by 25% YoY and by 5% QoQ
The stock's P/S is 19% above its 5-year quarterly average of 4.9 and 17% above its last 4 quarters average of 5.0
Efficiency
How efficient is UNITED THERAPEUTICS business performance
The ROIC has grown by 37% YoY and by 7% from the previous quarter
UNITED THERAPEUTICS's return on assets has increased by 17% YoY and by 3.8% QoQ
The ROE has grown by 12% YoY and by 2.1% from the previous quarter
The company's return on sales fell by 3.1% QoQ
Dividends
What is UTHR's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for UTHR.
Financial health
How did UNITED THERAPEUTICS financials performed over time
The company's total liabilities fell by 22% YoY
The quick ratio has increased by 7% since the previous quarter
The debt is 93% less than the equity
The debt has plunged by 50% YoY and by 20% from the previous quarter
UNITED THERAPEUTICS's debt to equity has shrunk by 50% YoY and by 22% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.